Third-party storage 3PL model introduced by Emirates Medicines Authority
The Emirates Medicines Authority has announced the adoption of a third-party storage 3PL model for the first time, and is now accepting license applications under its medical warehouse licensing services. The move allows facilities seeking distribution privileges to contract with existing, licensed medical warehouses instead of building standalone storage sites compliant with good distribution practices.
The policy change, confirmed by authority officials, applies to applicants across the United Arab Emirates and begins with inspection visits and a phased licensing review. Meanwhile, the regulator is collecting stakeholder feedback and refining operational scenarios to align requirements with both business needs and international pharmaceutical distribution norms.
Regulatory requirements and applicant obligations
Under the new framework, applicants pursuing distribution rights must enter into an agreement with at least one logistics provider designated as a third-party logistics partner. The third-party logistics partner, referred to as a 3PL, must be a medical warehouse already licensed by the Emirates Medicines Authority and meet specified storage and handling criteria.
Officials said that applications for third-party storage 3PL will be processed alongside standard medical warehouse licensing files. Therefore, applicants are expected to supply contractual documentation, demonstrate traceability arrangements, and show how temperature control and product security will be managed under the contracted model.
How inspections and framework updates will be conducted
Teams from the authority have begun conducting inspection visits tied to submitted applications, gathering on-the-ground observations and stakeholder recommendations. These assessments are intended to validate operational models, test different scenarios for outsourced storage, and identify any gaps in current guidance.
In addition, the regulator is updating checklists and procedural documents specific to third-party storage 3PL to ensure consistent application of standards. Furthermore, the adjustments aim to reduce ad hoc exceptions in licensing while enhancing oversight and compliance across the supply chain.
Benefits for industry and implications for pharmaceutical distribution
Adopting a third-party storage 3PL model is expected to lower operational costs for distributors and improve utilization of existing warehouse capacity. Therefore, smaller local firms and startups could access compliant storage solutions without the capital outlay required to develop independent facilities.
Furthermore, leveraging established logistics infrastructure in the UAE supports more resilient pharmaceutical distribution networks. The authority noted that the policy could attract foreign investment, support industry growth, and provide additional logistics options for companies operating in the region.
Alignment with international standards and compliance expectations
The authority’s approach emphasizes harmonizing local practices with international good distribution principles. Accordingly, third-party storage 3PL operators will be held to standards that reflect international guidance on storage conditions, documentation, and product integrity.
Therefore, the unified licensing pathway seeks to raise the overall level of compliance while streamlining administrative processes. The process also reinforces traceability and auditability, which are critical to safeguarding public health and ensuring consistent supply of medical products.
Practical considerations for companies and logistics providers
Companies considering the third-party storage 3PL option should evaluate contractual terms carefully, including liability, temperature monitoring responsibilities, and emergency response procedures. Meanwhile, warehouses pursuing or renewing licences must ensure their systems and records meet the updated medical warehouse licensing expectations.
Stakeholders are advised to engage early with the authority during the application process and to participate in consultations where possible. Additionally, businesses should map their supply-chain dependencies and test contingency arrangements under the outsourced storage arrangement.
What to watch next
The authority will continue phased inspections and publish revised checklists and guidance documents reflecting operational scenarios tested during the initial reviews. Observers should watch for updated application timelines, formal guidance on contractual minimums, and any sector-specific clarifications related to high-risk products or temperature-sensitive medicines.
Furthermore, industry groups and foreign investors will likely monitor how the new model affects market entry and logistics costs. Therefore, the initial months of implementation will be important for identifying practical issues and refining the regulatory framework.
Conclusion and forward outlook
The introduction of the third-party storage 3PL model marks a notable regulatory shift intended to modernize medical warehouse licensing and strengthen pharmaceutical distribution in the UAE. Going forward, the key next steps include completion of inspection cycles, publication of updated guidance, and a full rollout of the licensing pathway.
Stakeholders should watch for the authority’s formal updates and be prepared to submit contractual documentation with applications. Meanwhile, industry participants and logistics providers can expect ongoing regulatory engagement as the model is integrated into the country’s health product supply-chain oversight.
